Blockchain Registration Transaction Record

Soligenix CEO: Patient-Centric Reformulation Is Key to Drug Success

Soligenix CEO advocates for patient-centric drug development, highlighting reformulation of SGX945 from IV to subcutaneous to improve access and adherence in rare disease treatment.

This news highlights a critical evolution in healthcare: treating patients as partners in therapy design. For individuals with chronic rare diseases, the burden of frequent clinic visits for IV treatments can be overwhelming, affecting quality of life and treatment adherence. By shifting focus to convenient, home-based administration, as Soligenix is doing with SGX945, therapies become more sustainable in real-world settings. This approach can lead to better health outcomes, reduced healthcare system strain from missed treatments, and sets a new standard where drug efficacy is judged alongside patient quality of life. It signals to the entire biopharma industry that successful modern medicines must be designed for the people who use them daily.